Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....

ver descrição completa

Na minha lista:

Detalhes bibliográficos
Autor principal:	Qingchun Diao (5751701) (author)
Outros Autores:	Ruiling Jia (22654733) (author), Min Li (12799) (author), Peng Zhao (128233) (author), Fang Lu (45632) (author), Qin Zhang (58638) (author), Chunzhu Ning (22680917) (author), Juan Long (4017317) (author), Jiajia Li (184267) (author), Yan Huang (46805) (author), Yuyi Wang (462133) (author)
Publicado em:	2025
Assuntos:	Medicine Pharmacology Biotechnology Science Policy Biological Sciences not elsewhere classified Ivarmacitinib moderate-to-severe atopic dermatitis previous systemic treatments efficacy safety
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Seja o primeiro a partilhar um comentário!

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

Registos relacionados